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In a case–control study in Japan of brain tumours in relation to mobile phone use, we used a novel approach for estimating the
specific absorption rate (SAR) inside the tumour, taking account of spatial relationships between tumour localisation and intracranial
radiofrequency distribution. Personal interviews were carried out with 88 patients with glioma, 132 with meningioma, and 102 with
pituitary adenoma (322 cases in total), and with 683 individually matched controls. All maximal SAR values were below 0.1Wkg
 1,
far lower than the level at which thermal effects may occur, the adjusted odds ratios (ORs) for regular mobile phone users being 1.22
(95% confidence interval (CI): 0.63–2.37) for glioma and 0.70 (0.42–1.16) for meningioma. When the maximal SAR value inside the
tumour tissue was accounted for in the exposure indices, the overall OR was again not increased and there was no significant trend
towards an increasing OR in relation to SAR-derived exposure indices. A non-significant increase in OR among glioma patients in the
heavily exposed group may reflect recall bias.
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The rapid increase in mobile phone use has raised public concern
about their safety (Rothman et al, 1996; Violanti and Marshall,
1996; Repacholi, 1998; Blettner and Berg, 2000; Rothman, 2000).
Since only glial and meningial tissue close to the surface of the
head is exposed to relatively high electromagnetic fields (EMFs)
emitted from mobile phones, brain tumours, especially glioma and
meningioma, have received particular attention, along with
acoustic neurinoma and salivary gland tumours. To investigate
whether mobile phone users have an increased risk for these
tumours, a collaborative case–control study in 13 countries, the
INTERPHONE study, was initiated in 2000, coordinated by the
International Agency for Research on Cancer (IARC) and is still
underway (Cardis and Kilkenny, 1999; Christensen et al, 2005;
Lo ¨nn et al, 2005; Hepworth et al, 2006; Schuz et al, 2006;
Takebayashi et al, 2006; Cardis et al, 2007; Hours et al, 2007). Some
national reports are already published, with mixed findings.
A central issue has been how precisely to estimate the actual
EMF exposure, given the necessary reliance on self-reported use.
Different parts of the brain are known to be exposed to EMFs of
different magnitudes, related not only to which ear the phone is
placed on, but also to the characteristics of different mobile phone
models. The specific absorption rate (SAR) is widely accepted as a
dosimetric quantity in guidelines on EMF exposure (e.g., the
International Commission on Non-Ionizing Radiation Protection
(ICNIRP), 1998) in frequency ranges including those used for mobile
phones. The SAR, representing absorbed radiofrequency (RF) power
per unit mass of body tissue, is closely related to thermal effects. If
non-thermal effects are involved, SAR is also relevant, being as it is
closely correlated with internal electric and magnetic fields in tissue
near the radiation source (Mochizuki et al, 2002).
We have investigated whether mobile phone use increased brain
tumour risk in Japan. The study followed the common, core
protocol of the INTERPHONE study, but for estimating RF
exposure level in different areas of the brain in light of its great
variability, we adopted a new approach using a heterogeneous
head model (Japanese numerical TARO model’s head) (Nagaoka
et al, 2004).
METHODS
The study area encompassed Tokyo, consisting of 23 wards (the
metropolitan area) and 14 cities (the municipal area), along with
25 adjacent cities. In a preliminary survey, it was found that 30 of
the 172 hospital neurosurgery departments in Tokyo treated
approximately 90% of brain tumours in the area. Of these 30
departments, 21 agreed to participate in the study, and so it was
estimated that about 75% of the meningioma and glioma cases in
the study area would be covered. There were no differences in
patients’ socioeconomic status between participating and non-
participating hospitals. The case group consisted of newly
diagnosed meningiomas, gliomas, and pituitary adenomas at ages
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ment performed prospectively from December 2000 to November
2004. Participation was 58.7% (88 out of 150) for glioma, 77.6%
(132 out of 170) for meningioma, and 75.6% (102 out of 135) for
pituitary adenoma. The main reason for non-participation was
failure to contact the patients; for example, only 5% of glioma
eligible patients refused, whereas the rest (37%) were not informed
of the study during their hospital stay by their attending
physicians. The 10 cases found to have been diagnosed before
June 2000, more than 6 months before the study began, were
excluded from the analysis (with their controls) leaving 83 gliomas,
128 meningiomas, and 101 pituitary adenomas. Cases treated
surgically were verified histopathologically (codes of ICD-O 3rd
ed.: glioma, 9380–9384, 9390–9394, 9400–9401, 9410–9411,
9420–9424, 9430, 9440–9443, 9450–9451, 9460, 9480–9481;
meningioma, 9530–9539), but some were diagnosed by magnetic
resonance imaging. Among the 83 gliomas and 128 meningiomas,
78 (94%) and 118 (92.2%), respectively, underwent surgery. The
date of diagnosis was defined as when the tumour was first
identified radiologically.
Controls were selected from the general population by random
digit dialling, in which phone numbers for home fixed-phones were
generated randomly. Volunteers to act as controls were sought until
at least one for each case was identified who agreed to participate;
they were individually matched for age (within a 5-year range), sex,
and residence with the cases. Participation among contacted
controls was 52.5% (196 out of 373) for glioma, 51.6% (279 out of
541) for meningioma, and 49.4% (208 out of 421) for pituitary
adenoma. A brief questionnaire was administered over the phone or
via a self-administered paper questionnaire to those who did not
agree to face-to-face interviews, to compare phone use between
participants and non-participants among eligible controls. Basic
information on age, sex, brief history of mobile phone use, and
some life-style factors was available for 75.6, 73.0, and 72.0% of the
control for glioma, meningioma, and pituitary cases, respectively.
Each case subject and matched control was interviewed by the
same nurse or other health professional specifically trained for this
study. A Japanese version of the computer-assisted interview
system developed for the INTERPHONE study was used for the
face-to-face interviews (Cardis and Kilkenny, 1999). Subjects were
asked about their mobile phone use, including the dates of starting
and stopping to use each phone, the average duration and
frequency of calls, and other usage patterns in chronological
order. Use of the Personal Handy-phone System (PHS), a type of
cordless telephone system, was also recorded. Demographic
variables, medical history, and occupational history were also
recorded. Clinical information on the cases was obtained from the
relevant department.
When a case had over four matched controls, the latter was
reduced randomly to make a 4:1 ratio for each case. Thus, 83
gliomas had 163 matched controls, 128 meningiomas had 229
controls, and 101 pituitary adenomas had 161 controls.
Regular mobile phone use was defined as used at least once a
week for 6 months, and the reference date for phone use was set at
one year before diagnosis for each case to eliminate any effect of
disease in its prodromal stage; the same date being applied to
matched controls. Furthermore, for regular phone users, two
indices were created: cumulative length of use and cumulative call
time, the former defined as the time (years) since first use,
excluding any period when it was not regularly used. For recent
use, either the reference date or the stop date of the last phone,
whichever came first, was adopted as the end of use date. The
cumulative call time was the total call durations (hours) since first
use, which was the sum of call durations with all phones. Typically,
the daily call duration was calculated by multiplying the average
call duration per call by the number of calls per day, the call
duration for each phone being the product of the daily call
duration and the length of use.
An odds ratio (OR), in which the reference category was the
non-user, unless otherwise specified, was calculated with the
conditional logistic regression model, in which the educational
level (junior high school, high school, 2-year college, 4-year college
or graduate school) and marital status (married or others) were
simultaneously adjusted for as categorical variables.
To examine for an association with laterality of phone use, we
employed a conditional logistic regression analysis, in which EMF
exposure was assumed only when the self-reported side of phone
use was the same as the tumour’s (ipsilateral use). A similar
analysis was performed for contralateral use, with exposure
assumed when the self-reported side of phone use was the
opposite of the tumour’s. If both ears were reported used for
phone use, exposure was assumed for both analyses.
To account for the three-dimensional, spatial relationship
between tumour and RF exposure distribution, we attempted to
estimate the maximal SAR value inside the tumour. Since pituitary
adenomas occur in the sellar region, where RF exposure is
negligible, SAR was estimated only for gliomas and meningiomas
as follows. Mobile phones were categorised into a small number of
groups in terms of SAR distribution (Wake et al, 2006), since each
phone model has a different intracranial SAR distribution and it is
impossible to estimate the actual SAR distributions for the
hundreds of mobile phones used by the cases and controls. We
used the SAR distribution data from 76 phones on the Japanese
market in January 2001 measured with a phantom using standard
procedure for compliance testing in Japan similar to the
international standard procedure (IEC 62209). Surface SAR was
measured in a limited region near the phone, and cube SAR data
was measured in a small three-dimensional region around the
maximal SAR location. The cluster analysis was then applied to
categorise the phones, in which SAR distributions were repre-
sented by location of maximal SAR, surface area larger than 50% of
the maximal SAR, or depth larger than 50% of the maximal SAR.
The results of categorisation depended on the conditions of phone
use. Mobile phones could be classified into four categories
assuming normal use condition as cheek position with antenna
extracted: (1) flip/flop phones of both 800-MHz and 1.5-GHz band
with an antenna in the centre; (2) flip/flop phones of 800-MHz
band with an antenna on the top; (3) 1.5-GHz band phones with an
antenna on top; and (4) straight phones of 800-MHz band with an
antenna on top. On the basis of this finding, a hypothetical three-
dimensional SAR distribution was constructed for each category of
mobile phone on the above head model, Japanese numerical TARO
model’s head (Nagaoka et al, 2004). First, we estimated three-
dimensional SAR distribution for each phone in TARO model’s
head with the measured SAR data (Wake et al, 2005). The surface
SAR data measured in the limited regions of the phantom was
extrapolated to its whole head, and was further projected to the
surface of TARO model’s head. Then, SAR in depth direction was
estimated assuming exponential decay of the first three layers.
Finally, SAR distribution for each phone category was obtained by
averaging SAR distributions for all phones belonging to the
category (Varsier et al, 2007).
Each mobile phone actually used was allocated to one of four
categories and the hypothetical SAR distribution assigned, taking
into account which ear was in contact (Varsier et al, 2007). The
tumour location for each case was measured on a 12 computed
tomography scan-cut chart model. Because of their differences, the
TARO’s head was transformed to match the chart model by
projection. Then the SAR value inside the tumour was estimated at
a 1-cm resolution and the maximal SAR was identified for each
phone. For matched controls, the maximal SAR value was
estimated for the tumour location of the corresponding cases.
Three exposure indices were constructed based on the SAR
distribution inside the tumour. The mean maximal SAR (mean
maxSAR) was calculated for each subject by averaging the maximal
SAR value over the mobile phone used by the subject. The
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use weighted by maxSAR, or calculated by summing the product of
maxSAR and length of use in years for each phone over the
different mobile phones used by each subject. The cumulative
maxSAR-hour was defined as the cumulative call time weighted by
maxSAR, or calculated by summing the product of the maxSAR
and call time in hours for each phone over the different mobile
phones used by each subject.
In a case-only analysis, the mean maxSAR, cumulative maxSAR-
year, and cumulative maxSAR-hour were estimated for the actual
and for a hypothetical tumour location, which was the mirror
image of the tumour on the opposite side across the sagittal plane.
The rationale was that the above SAR indices should have a higher
value for the actual than for the hypothetical tumour location if RF
exposure increased tumour risk. Each of the three indices was
dichotomised into high and low values using the median
distribution among the controls as the cut-off point: 0.0012
(glioma) and 0.0011 (meningioma) for average maxSAR; 0.0059
(glioma) and 0.0041 (meningioma) for cumulative maxSAR-year;
and 0.447 (glioma) and 0.146 (meningioma) for cumulative
maxSAR-hour; the McNemar test was used for comparisons.
Statistical analyses used STATA/SE version 8.2 (College Station,
StataCorp, TX, USA). All statistical tests were two-sided; separate
analyses were performed including and excluding the PHS system,
which has a much lower emission power than mobile telephones,
and as the results showed no substantial differences (data not
shown), those analyses excluding the PHS system are presented
here.
This study was approved by the Institutional Review Boards of
the participating institutes. Its protocol was reviewed by the
research group’s Privacy Protection Subcommittee, which also
monitored the procedures employed.
RESULTS
The basic characteristics of the cases and controls are shown in
Table 1. For time-varying items, the situations at the reference date
are displayed. Cases and controls showed no substantial differ-
ences with respect to age, sex, residential area, educational level, or
marital status. Educational level and marital status were con-
sidered to reflect their socioeconomic status and were selected a
priori as confounding variables. The overall participation rate of
the controls in the full study was 51.2%, but an additional 28.8% of
eligible controls answered the brief survey about their mobile
phone use. The age- and sex-adjusted proportions of regular users
were 66.4% (glioma) and 55.1% (meningioma) in the brief survey,
and were comparable with 65% (glioma) and 51.5% (meningioma)
in the full study.
The adjusted OR (95% confidence interval (CI)) for regular
mobile phone use was 1.22 (0.63–2.37) for glioma, 0.70 (0.42–
1.16) for meningioma, and 0.90 (0.50–1.61) for pituitary adenoma,
Table 1 Case–control comparison of basic characteristics at reference date
Glioma Meningioma Pituitary adenoma
Case no. Control no. Case no. Control no. Case no. Control no.
Age (years)
3 0 – 3 9 2 75 6 1 42 6 2 64 3
4 0 – 4 9 1 83 8 3 25 7 1 93 0
5 0 – 5 9 2 74 8 5 49 7 4 97 3
6 0 – 6 9 1 12 1 2 84 971 5
Sex
Male 44 85 29 48 62 101
Female 39 78 99 181 39 60
Education
Junior high 10 10 7 20 6 9
High 40 78 91 150 56 74
College+ 33 75 30 59 39 78
Marital status
Married 59 125 95 174 71 134
Others 24 38 33 55 30 27
Residential area
Tokyo (metro) 36 63 61 96 49 71
Tokyo (municipal) 9 22 14 27 13 24
Chiba 8 20 12 20 9 12
Kanagawa 11 25 24 41 13 20
Saitama 19 33 17 45 17 34
Smoking status
Non-smoker 59 125 95 174 71 134
Ex-smoker 24 38 33 55 30 27
Current smoker 24 38 33 55 30 27
Timing of interview
December 2000–November 2001 25 8 32 20 32 16
December 2001–November 2002 17 31 27 45 22 40
December 2002–November 2003 29 76 36 59 32 40
December 2003–November 2004 12 39 33 95 15 59
December 2004–March 2005 0 9 0 10 0 6
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The adjusted OR did not change significantly when the reference
date was set at 5 years before diagnosis: 0.90 (0.47–1.72) for
glioma, 1.32 (0.72–2.43) for meningioma, and 0.96 (0.52–1.79) for
pituitary adenoma.
When cumulative length of use and call time were categorised
into quartiles according to distribution among the controls for
each tumour type, as shown in Table 2, no increasing trend was
found in risks of glioma, meningioma, or pituitary adenoma. In
addition, the OR for a cumulative use of 10 years or longer was
0.58 (0.09–3.86) for glioma, 1.35 (0.31–5.93) for meningioma, and
1.15 (0.22–5.18) for pituitary adenoma, although the numbers
were very small: 2 cases and 6 controls for glioma; 4 cases and 4
controls for meningioma; and 4 cases and 5 controls for pituitary
adenoma. The OR for a cumulative call time of 2000h or more was
1.47 (0.41–5.28) for glioma, 0.64 (0.14–3.86) for meningioma, and
1.41 (0.46–4.37) for pituitary adenoma, again on the basis of very
small numbers: 6 cases and 9 controls for glioma; 3 cases and 6
controls for meningioma; and 9 cases and 12 controls for pituitary
adenoma.
No subject had used analogue-type phones alone. No difference
in OR was identified for use of both analogue and digital phones vs
digital phones only: 0.83 (0.23–3.00) vs 1.29 (0.66–2.53) for
glioma; 1.06 (0.36–3.09) vs 0.67 (0.40–1.13) for meningioma; and
0.54 (0.17–1.75) vs 0.95 (0.53–1.71) for pituitary adenoma,
respectively.
In the laterality analysis, in which it was simply assumed that
exposure existed when the tumour location (left or right) matched
that for phone use, the ORs for ipsilateral and contralateral use
were 1.24 (0.67–2.29) and 1.08 (0.57–2.03) for glioma, and 1.14
(0.65–2.01) and 0.65 (0.37–1.13) for meningioma, respectively.
For the analysis using maxSAR-derived exposure indices, 77 of
83 glioma cases and 125 of 128 meningioma cases with tumour
location charts available, with 151 and 221 controls, respectively,
were included. Mean maxSAR was estimated for each case, ranging
from 1.2 10
 6 to 0.0599Wkg
 1 for glioma and 6.8 10
 7 to
0.0619Wkg
 1 for meningioma (Figure 1). The distribution of
cumulative maxSAR-year and cumulative maxSAR-hour are also
presented in Figure 1. The non-exposed group consisted of non-
users and regular users whose mean maxSAR was extremely low
(less than 1 10
 4): 34 (44.2%) cases and 71 (47.0%) controls for
glioma, and 81 (64.8%) cases and 127 (75.5%) controls for
meningioma. The OR for exposed to non-exposed was 1.28 (0.63–
2.57) for glioma and 0.72 (0.42–1.24) for meningioma. In addition,
the exposed group was divided into four subgroups on the basis of
the quartiles of distribution of maxSAR-derived indices among the
controls. No increasing trend was found for either glioma or
meningioma risk with an increase in mean maxSAR, cumulative
maxSAR-year, or cumulative maxSAR-hour (Table 3).
Since the ORs for the highest quartile were all higher than unity
for glioma (1.04 (0.37–2.93) for mean maxSAR, 1.75 (0.63–4.85)
for cumulative maxSAR-year, and 1.55 (0.57–4.19) for cumulative
maxSAR-hour), we further examined risk associated with a very
high exposure. When categorised by cut-off points of 0.001 and
0.01Wkg
 1, the adjusted OR for those with mean maxSAR over
0.01Wkg
 1 as compared with the non-exposed was 0.87 (0.28–
2.75) for glioma and 1.17 (0.40–3.39) for meningioma, indicating
no substantial increase in risk. When categorised by cut-off points
Table 2 Case–control comparison of the indices of mobile phone use
Glioma Menigioma Pituitary adenoma
Case no. Control no. OR (95% CI) Case no. Control no. OR (95% CI) Case no. Control no. OR (95% CI)
Mobile phone use
Non-user 27 57 1.0 73 111 1.0 39 56 1.0
Regular user 56 106 1.22 (0.63–2.37) 55 118 0.70 (0.42–1.16) 62 105 0.90 (0.50–1.61)
Cumulative length of use in years
a
Non-user 27 57 1.0 73 111 1.0 39 56 1.0
Lowest 11 25 0.92 (0.37–2.28) 6 28 0.39 (0.10–1.01) 14 25 0.86 (0.39–1.88)
Mid-low 21 27 1.65 (0.70–3.90) 13 27 0.70 (0.31–1.58) 13 27 0.75 (0.31–1.81)
Mid-high 17 25 1.85 (0.78–4.40) 16 33 0.73 (0.35–1.53) 22 26 1.64 (0.74–3.66)
Highest 7 29 0.60 (0.20–1.78) 20 30 1.05 (0.52–2.11) 13 27 0.75 (0.31–1.82)
P for trend¼0.743 P for trend¼0.800 P for trend¼0.885
Cumulative call time in hours
b
Non-user 27 57 1.0 73 111 1.0 39 56 1.0
Lowest 15 26 1.57 (0.66–3.74) 12 28 0.74 (0.33–1.67) 15 26 1.00 (0.46–2.16)
Mid-low 14 27 0.88 (0.35–2.22) 15 31 0.66 (0.32–1.37) 14 26 0.97 (0.40–2.32)
Mid-high 9 25 0.90 (0.34–2.36) 11 29 0.55 (0.24–1.26) 12 26 0.72 (0.31–1.70)
Highest 18 28 1.74 (0.71–4.26) 17 30 0.92 (0.43–1.96) 21 27 1.33 (0.58–3.09)
P for trend¼0.483 P for trend¼0.356 P for trend¼0.865
Type of mobile phone used
Non-user 27 57 1.0 73 111 1.0 39 56 1.0
Analogue+digital 6 13 0.83 (0.23–3.00) 7 9 1.06 (0.36–3.09) 5 14 0.54 (0.17–1.75)
Digital 50 93 1.29 (0.66–2.53) 48 109 0.67 (0.40–1.13) 57 91 0.95 (0.53–1.71)
Tumour laterality and side of mobile phone use
Reference 49 113 1.0 97 178 1.0 (not done)
Ipsilateral use
c 31 50 1.24 (0.67–2.29) 31 50 1.14 (0.65–2.01)
Reference 55 114 1.0 102 162 1.0 (not done)
Contralateral use
d 25 49 1.08 (0.57–2.03) 26 60 0.65 (0.37–1.13)
Abbreviations: CI¼confidence interval; OR¼odds ratio adjusted for education and marital status.
aCut-off points for quartiles (divided on the basis of the distribution of the
control group): 2.2, 4.7, and 6.5 years for glioma; 1.6, 3.2, and 5.2 years for meningioma; 2.4, 4.5, and 7.2 years for pituitary adenoma.
bCut-off points for quartiles (divided on the
basis of the distribution of the control group): 32, 160, and 620h for glioma; 19, 61, and 260h for meningioma; 39, 190, and 560h for pituitary adenoma.
cIpsilateral use: tumour
location (left/right) was the same as the side of mobile phone use.
dContralateral use: tumour location (left/right) was the opposite as the side of mobile phone use.
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yof 0.001, 0.01, and 0.1Wkg
 1-year, the adjusted OR for those with
cumulative maxSAR-year over 0.1Wkg
 1-year as compared with
the non-exposed was 0.63 (0.14–2.93) for glioma and 2.72 (0.47–
15.98) for meningioma, again indicating no substantial increase in
risk. When categorised by cut-off points of 0.1, 1, and 10Wkg
 1-
hour, on the other hand, the adjusted OR for the highest vs lowest
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Figure 1 Distribution of estimated maxSAR-derived exposure indices in the tumour. (A) Glioma; (a) mean maxSAR; (b) cumulative maxSAR-year; (c)
cumulative maxSAR-hour. (B) Meningioma; (a) mean maxSAR; (b) cumulative maxSAR-year; (c) cumulative maxSAR-hour.
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for glioma, on the basis of 7 cases (9.1%) and 4 controls (2.7%) in
the highest category. No increase in risk was found for
meningioma: 1.14 (0.28–4.61), on the basis of 4 cases (3.2%) and
6 controls (2.7%).
In the case-only analysis, no differences were identified when
three dichotomised maxSAR-derived indices were compared
between the actual and hypothetical opposite tumour location
(as shown in Table 4).
DISCUSSION
No consistent increase was observed in the overall risk of glioma
or meningioma among mobile phone users, nor increasing trend
in risk in relation to cumulative length of use or cumulative call
time. We further estimated the SAR in the intracranial space with a
resolution of 1cm
3, and constructed three SAR-derived exposure
indices (mean maxSAR, cumulative maxSAR-year, and cumulative
maxSAR-hour) to estimate the cumulative exposure level inside
the tumour as precisely as possible. Again, no substantial increase
in risk was observed for glioma or meningioma. Maximal SAR
inside the tumour was estimated to be lower than 0.1Wkg
 1 in all
eligible cases, far below the ICNIRP’s recommended value of
2Wkg
 1 for localised SAR (head and trunk) in the general
population.
This is to our knowledge, the first epidemiological study to take
into account the different exposure levels inside the intracranial
space. Exposure is localised close to the relevant ear, whereas
glioma and meningioma develop at a variety of sites. Estimation of
the actual exposure level inside the tumour is essential, therefore,
to avoid exposure misclassification, which bias risk estimates
towards the null. Nevertheless, recall bias is a possibility and
awareness of tumour location among the cases might have affected
their recall concerning which ear they used for mobile phone calls.
The non-significant increase in OR of 5.84 for those with
cumulative maxSAR-hour over 10Wkg
 1-hour as compared with
the non-exposed group could reflect recall bias, since increased OR
was observed only for this heavily exposed group; it needs to be
interpreted with caution.
Table 3 Risk of brain tumour with relation to mobile phone use, considering estimated maximal SAR in the tumour as an exposure index
Glioma Meningioma
Case no. Control no. OR (95% CI) Case no. Control no. OR (95% CI)
Mean maxSAR
a
Non-exposed
b 34 71 1.0 81 127 1.0
Lowest 10 20 0.91 (0.32–2.56) 7 23 0.40 (0.15–1.09)
Mid-low 7 20 0.81 (0.26–2.53) 9 24 0.48 (0.17–1.32)
Mid-high 15 20 2.98 (0.98–9.01) 13 23 0.94 (0.39–2.29)
Highest 11 20 1.04 (0.37–2.93) 15 24 1.10 (0.50–2.41)
P for trend¼0.402 P for trend¼0.402
Non-exposed
b 34 71 1.0 81 127 1.0
o0.001 17 37 0.94 (0.40–2.24) 16 44 0.46 (0.21–1.00)
0.001–0.01 17 27 2.30 (0.86–6.19) 21 38 0.86 (0.41–1.80)
X0.01 9 16 0.87 (0.28–2.75) 7 12 1.17 (0.40–3.39)
P for trend¼0.492 P for trend¼0.749
Cumulative maxSAR-year
c
Non-exposed
b 34 71 1.0 81 127 1.0
Lowest 10 20 1.08 (0.37–3.16) 3 23 0.18 (0.05–0.63)
Mid-low 10 20 1.26 (0.46–3.43) 18 24 1.10 (0.48–2.50)
Mid-high 8 20 1.07 (0.33–3.45) 8 23 0.56 (0.21–1.48)
Highest 15 20 1.75 (0.63–4.85) 15 24 1.07 (0.48–2.36)
P for trend¼0.306 P for trend¼0.904
Non-exposed
b 34 71 1.0 81 127 1.0
o0.001 7 19 0.66 (0.21–2.09) 3 23 0.17 (0.05–0.61)
0.001–0.01 14 26 1.53 (0.61–3.85) 23 44 0.76 (0.37–1.54)
0.01–0.1 18 28 2.09 (0.75–5.83) 13 22 0.93 (0.39–2.20)
X0.1 4 7 0.63 (0.14–2.93) 5 5 2.72 (0.47–15.98)
P for trend¼0.332 P for trend¼0.904
Cumulative maxSAR-hour
d
Non-exposed
b 34 71 1.0 81 127 1.0
Lowest 8 20 0.89 (0.30–2.64) 9 23 0.63 (0.26–1.52)
Mid-low 16 20 1.82 (0.73–4.49) 14 24 0.78 (0.33–1.84)
Mid-high 6 20 0.71 (0.23–2.18) 10 23 0.76 (0.33–1.78)
Highest 13 20 1.55 (0.57–4.19) 11 24 0.70 (0.30–1.63)
P for trend¼0.437 P for trend¼0.402
Non-exposed
b 34 71 1.0 81 127 1.0
o0.1 14 30 1.09 (0.44–2.70) 22 46 0.67 (0.34–1.32)
0.1–1 14 22 1.30 (0.52–3.23) 9 24 0.66 (0.28–1.59)
1–10 8 24 0.92 (0.31–2.69) 9 18 0.71 (0.27–1.89)
X10 7 4 5.84 (0.96–35.60) 4 6 1.14 (0.28–4.61)
P for trend¼0.244 P for trend¼0.484
Abbreviations: CI¼confidence interval; OR¼odds ratio adjusted for education and marital status; SAR¼specific absorption rate.
aCut-offs for quartiles (on the basis of the
distribution of the control group): 0.00036, 0.0012, and 0.008 for glioma; 0.00049, 0.0011, and 0.0048 for meningioma.
bNon-exposed group includes mobile phone users whose
maximal SAR was estimated to be o0.0001Wkg
 1.
cCut-offs for quartiles (on the basis of the distribution of the control group): 0.0012, 0.0059, and 0.025 for glioma; 0.001,
0.0041, and 0.014 for meningioma.
dCut-offs for quartiles (on the basis of the distribution of the control group): 0.028, 0.447, and 2.18 for glioma; 0.014, 0.146, and 1.12 for
meningioma.
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could have affected participation differentially among cases and
controls, with consequently a biased risk estimate. During the
random digit dialling control selection, we tried to ensure that this
did not vary between those who were regularly at home and those
who were out more often: mobile phone users tend to be more
active and busier, staying at home for shorter periods than non-
users, and risk could be overestimated if controls included an
unbalanced number of non-users. Although participation among
controls in the full interview remained around 50%, we were able
to examine its impact on risk estimates by using the information
obtained from the brief questionnaire completed by non-
participating controls. The age- and sex-adjusted proportions of
regular mobile phone users among the control candidates who did
not participate in the full interview but agreed to respond to the
brief questionnaire (28.8% of eligible controls) were 66.4%
(glioma) and 55.1% (meningioma) as compared with 65.0%
(glioma) and 51.5% (meningioma) for the controls who partici-
pated in the full, face-to-face interview (51.2% of eligible controls),
respectively, indicating that the interviewed controls did not
constitute a biased sample in terms of mobile phone use. Adjusted
ORs for regular mobile phone users did not vary significantly,
irrespective of whether the controls were taken as those who
responded to the brief questionnaire or those who took part in the
full interview (the ORs were 1.21 for glioma and 0.70 for
meningioma).
To date, several case–control studies have been reported from
the United States (Muscat et al, 2000; Inskip et al, 2001), Finland
(Auvinen et al, 2002), and Sweden (Hardell et al, 1999, 2002, 2003,
2004) before the INTERPHONE study. Two US studies showed
negative results for the overall risk of brain tumours, whereas in a
Finnish population register-based study, the OR for glioma with
relation to ever use of analogue mobile phones was 2.1 (95% CI:
1.3–3.4). Risk was estimated for the left/right laterality of the
tumour or for the affected lobe in relation to that of mobile phone
use, but no increased risk was observed for tumours on the same
side as phone use. In a series of Swedish studies, the risk of
tumours in the temporal area on the same side as that used for
mobile phone calls was increased for analogue phones, OR 2.3
(95% CI: 1.2–4.1). However, no increased risks by histological
types were observed (Hardell et al, 2003).
Four studies from the INTERPHONE study showed no increased
overall risk of glioma or meningioma in relation to regular mobile
phone use (Christensen et al, 2004, 2005; Hepworth et al, 2006;
Schuz et al, 2006), although glioma risk increased non-significantly
(OR¼2.20; 95% CI: 0.94–5.11) among long-term users (10 years
or more), but no excess risk was found for temporal lobe tumours,
considered to be exposed to the highest radio frequency (RF)–
EMF (Schuz et al, 2006). In a Swedish study, the OR for glioma on
the same side as mobile phone use increased to 1.8 (95% CI: 0.8–
3.9) among long-term (X10 years) mobile phone users, but the
corresponding OR for glioma on the opposite side was found to
decrease to 0.6 (95% CI: 0.3–1.4) among long-term users (Lo ¨nn
et al, 2005). In a UK study, the OR for glioma on the same side as
mobile phone use was 1.24 (95% CI: 1.02–1.52), but for gliomas on
the opposite side, it decreased significantly to 0.75 (95% CI: 0.61–
0.93) (Hepworth et al, 2006). In both studies, it was suggested that
such ‘complementary risks’ above and below unity could reflect
recall bias, in which glioma patients tended to recall that they used
mobile phones on the same side as the tumour location simply
because they knew where the tumour was. In summary, the
findings to date on mobile phone use and glioma and meningioma
risks are inconsistent.
Most studies of the non-thermal effects of RF–EMF indicate no
direct DNA effects such as mutagenicity or genotoxicity of RF–
EMF exposure in the range of 800–1900MHz and an SAR of less
than 2Wkg
 1. There is also little evidence for indirect DNA
effects, including alterations in gene expression, cell proliferation,
or apoptosis (Laszlo et al, 2005; Chauhan et al, 2006; Lixia et al,
2006; Qutob et al, 2006; Joubert et al, 2007). Thus, laboratory
studies do not support the possibility that mobile phone use
increases the risk of brain tumours.
In conclusion, we observed no increase in overall risk of glioma
or meningioma in relation to regular mobile phone use among our
Japanese subjects.
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Table 4 Case-only analysis to compare the distribution of maximal SAR-related indices within the tumour and its axis-symmetrical location
a
Glioma Meningioma
Axis-symmetrical tumour location
b Axis-symmetrical tumour location
b
Mean maxSAR
X0.0012 o0.0012 X0.0011 o0.0011
Actual tumour X0.0012 11 15 Actual tumour X0.0011 17 11
Location o0.0012 11 13 Location o0.0011 10 14
P¼0.433 P¼0.827
Cumulative maxSAR-year
X0.0059 o0.0059 X0.0041 o0.0041
Actual tumour X0.0059 11 12 Actual tumour X0.0041 12 11
Location o0.0059 10 17 Location o0.0041 12 17
P¼0.670 P¼0.835
Cumulative maxSAR-hour
X0.447 o0.447 X0.146 o0.146
Actual tumour X0.447 10 9 Actual tumour X0.146 9 12
Location o0.447 9 22 Location o0.146 9 22
P¼1.000 P¼0.664
Abbreviation: SAR¼specific absorption rate.
aThe study subjects analysed here were limited to the cases with regular mobile phone use whose maximal SAR distribution was
estimated.
bHypothetical tumour location on the opposite side of the actual tumour across the sagittal plane.
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